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Background: Recently, the relationship between gut microbiota and obesity has been highlighted. The present
randomized, double-blind, placebo-controlled study aimed to evaluate the efficacy of transglucosidase (TGD) in
modulating blood glucose levels and body weight gain in patients with type 2 diabetes mellitus (T2DM) and to
clarify the underlying mechanism by analyzing the gut microbiota of T2DM patients.
Methods: This study included 60 patients who received placebo or TGD orally (300 or 900 mg/day) for 12 weeks,
and blood and fecal samples were collected before and after 12 weeks. Comparisons of fecal bacterial communities
were performed before and after the TGD treatment and were performed between T2DM patients and 10 healthy
individuals, using the terminal-restriction fragment length polymorphism analysis.
Results: The Clostridium cluster IV and subcluster XIVa components were significantly decreased, whereas the
Lactobacillales and Bifidobacterium populations significantly increased in the T2DM patients compared with the
healthy individuals. By dendrogram analysis, most of the healthy individuals (6/10) and T2DM patients (45/60) were
classified into cluster I, indicating no significant difference in fecal bacterial communities between the healthy
individuals and the T2DM patients. In the placebo and TGD groups, the bacterial communities were generally
similar before and after the treatment. However, after 12 weeks of TGD therapy, the Bacteroidetes-to-Firmicutes
ratio in the TGD groups significantly increased and was significantly higher compared with that in the placebo
group, indicating that TGD improved the growth of the fecal bacterial communities in the T2DM patients.
Conclusions: Therefore, TGD treatment decreased blood glucose levels and prevented body weight gain in the
T2DM patients by inducing the production of oligosaccharides in the alimentary tract and modulating gut
microbiota composition.
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Previously, we introduced a novel strategy using Aspergillus
niger transglucosidase (TGD) to produce oligosaccharides
from starch in the digestive tract of humans to decrease
postprandial blood glucose levels in individuals with im-
paired glucose tolerance and at high risk of developing type
2 diabetes mellitus (T2DM) [1]. Furthermore, we demon-
strated that TGD administration decreases glycosylated
hemoglobin (HbA1c) and insulin levels in T2DM patients
[2]. We suggested that the mechanism underlying the re-
duction in the total amount of orally ingested calories is the
consequent transformation of digestible substrate to indi-
gestible fiber in the alimentary tract. Our human microbial
genomes encode many metabolic capacities that we have
not fully evolved. There may be evidence to clarify why
unabsorbable carbohydrates improve postprandial hyper-
glycemia in diabetes patients [3], which is also the mechan-
ism that explains the effects of TGD. Recently, there is
increasing evidence that is indicative of the relationship be-
tween obesity and gut microbiota [4-7]. Comparisons of the
gut microbiota between genetically obese mice and their
lean littermates, and between obese and lean human volun-
teers revealed that obesity is associated with changes in the
relative abundance of the 2 dominant bacterial divisions,
Bacteroidetes and Firmicutes. Colonization of adult germ-
free mice with a distal gut microbial community harvested
from conventionally raised mice produced a dramatic in-
crease in body fat within 10–14 days, despite an associated
decrease in food consumption [4]. These findings have led
us to propose that the gut microbiota of obese individuals
may be more efficient at extracting energy from a given diet
than those of lean individuals.
This study aimed to assess the gut microbiota of T2DM
patients and healthy individuals by terminal-restriction
fragment length polymorphism (T-RFLP) analysis of fecal
samples. Furthermore, we aimed to clarify the mechanism
of the effect of TGD treatment by analyzing fecal micro-
biota and comparing fecal microbiota composition before
and after TGD treatment.
Methods
The present study was designed as a randomized, double-
blind, placebo-controlled trial and was conducted in Japan.
The ethics review committee of the Nagoya City University
Graduate School of Medical Sciences granted approval of
this study, and informed consent was obtained from all the
subjects. TGD (3,000,000 U/g) was purchased from Amano
Enzyme Inc. (Nagoya, Japan). Two types of capsules
containing TGD (50 and 150 mg) and a placebo capsule
were prepared. Patients took 2 capsules after every meal for
12 weeks, and fecal and blood sampling was performed be-
fore and at the end of the study. The patient enrollment cri-
teria and study design used were described previously [1].
Briefly, all the eligible patients had an established diagnosisof T2DM according to the Japanese Diabetes Society’s cri-
teria for diabetes mellitus; HbA1c levels of 5.8–7.5% at
screening; stable dosages of medication for at least 1
month; and stable diabetes condition for at least 3 months
(change in HbA1c level by <1.0%). We excluded patients
who had a history of gut resection. Based on our previous
in vitro and in vivo experiments [2,8], we used TGD dos-
ages of 300 and 900 mg/day. Using simple randomization
technique, the patients were randomized into 3 groups
(1:1:1 proportion) according to the treatment received as
follows: 100 mg of TGD, 300 mg of TGD, and placebo 3
times a day after the main meal for 12 weeks. The capsules
containing transglucosidase and placebo were prepared by
Adaptogen pharmaceutical Co., LTD (Tajimi, Japan), and
allocation was blinded until the end of study. The statisti-
cian generated the randomization list managed by clinical
research coordinator. Blood and feces samplings were
performed before and at the end of the study. The primary
outcome was the change in HbA1c level (previously
reported). Patients whose fecal samples were collected be-
fore the treatment in our previous study were included in
the evaluation. Important secondary outcomes included the
change in various other metabolic parameters and fecal
microbiota. For comparison, fecal samples were collected
from healthy volunteers, who had no abnormality as deter-
mined by medical examination. Fecal microbiota were ana-
lyzed using T-RFLP. To evaluate nutrient intake, a data-
based short food frequency questionnaire [9] was used. The
patients received stable dosages of diabetes medication
throughout the study. The sample size calculation was
based on a previous study [2,6], and based on alpha of 0.05
with a power of 80%. Taking into account a drop-out of
10%, a total sample size of 66 patients will be randomized.
Fecal DNA extraction
The fecal samples were suspended in 4 M guanidinium
thiocyanate, 100 mM Tris–HCl (pH 9.0), and 40 mM
EDTA after washing 3 times with sterile distilled water and
then beaten with glass beads, using a mini bead beater
(BioSpec Products). Thereafter, DNA was extracted from
the bead-treated suspension using benzyl chloride, as de-
scribed by Zhu et al. [10]. The DNA extract was then puri-
fied using a GFX polymerase chain reaction (PCR) DNA
and Gel Band Purification Kit (Amersham Biosciences).
The final concentration of each DNA sample was adjusted
to 10 ng/μL.
T-RFLP analysis
The amplification of the 16SrDNA, digestion of restriction
enzymes, size fractionation of T-RFs, and analysis of T-
RFLP data were performed according to the protocol de-
scribed by Nagashima et al. [11]. Briefly, polymerase chain
reaction (PCR) was performed using the total fecal
DNA (10 ng/μL) and primers of 516f (5′-TGC
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516–532) and 1510r (5′-GGTTACCTTGTTACGACTT-
3′; E. coli positions, 1510–1492). The 5′-ends of the for-
ward primers were labeled with 6′-carboxyfluorescein,
which was synthesized by Applied Biosystems (Tokyo,
Japan). The amplified 16S rDNA genes were purified using
the GFX PCR DNA and Gel Band Purification Kit (GE
Healthcare Bio-Sciences, Tokyo, Japan) and redissolved in
30 μL of distilled water. The purified PCR products (2 μL)
were digested with 10 U of BslI at 55°C for 3 h. The length
of the T-RF was determined using an ABI PRISM 3130 × 1
genetic analyzer (Applied Biosystems, CA, USA) in
GeneScan mode. Standard size markers were used
(MapMarker X-Rhodamine Labeled 50–1000 bp,
BioVentures, TN, USA). The fragment sizes were estimated
using the local southern method of the GeneMapper soft-
ware (Applied Biosystems, CA, USA). The T-RFs were di-
vided into 30 operational taxonomic units (OTUs),
according to the methods described by Nagashima et al.
[11]. The OTUs were quantified as the percentage values of
an individual OTU per total OTU area, expressed as peak
percent area under the curve (%AUC). Cluster analyses
were performed using the software GeneMaths (Applied
Maths, Belgium), based on the BslI T-RFLP patterns. The
Pearson similarity coefficient analysis and unweighted
pair-group method with arithmetic means were used to
establish the type of dendrogram.
Statistical analysis
The patients’ characteristics and nutrient intake profiles
were compared between the placebo and 2 TGD groups,
using the chi-square test or 2-way ANOVA and Bonferroni
post hoc test. The relative abundances of specific bacterialAssessed for e
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Figure 1 Flow diagram of patients included.groups were reflected through their T-RF peak areas, and
the percentage values were compared between the placebo
and 2 TGD groups using the 2-way ANOVA and
Bonferroni post hoc test. A p < 0.05 was considered statisti-
cally significant.
Results
In the previous study, between December 2007 and Marchi
2009, a total of 74 T2DM patients from our outpatient
clinic were recruited and 66 (38 men, 28 women) were ran-
domized into the following groups: 21, placebo group; 23,
TGD300 group to receive 300 mg of TGD a day; and 22,
TGD900 group to receive 900 mg of TGD a day. Six pa-
tients did not complete the study, with 5 discontinuing the
treatment and 1 was hospitalized due to another disease
and left the study. In randomized 66 patients, 60 patients
(35 men and 25 women, 20; placebo groups 20; TGD300
group, 20; TGD900 group) whose fecal samples were col-
lected before the treatment were included in the evaluation
before treatment. As 11 patients were lost the fecal sam-
pling after treatment, 49 patients (16; placebo group, 16;
TGD300 group, 17; TGD900 group) were included in the
evaluation after treatment (Figure 1).
The baseline clinical characteristics and biochemical
values of the 3 groups had a similar distribution with regard
to age, sex, body mass index (BMI), medical history, and
biochemical data, including HbA1c, fasting blood glucose,
and insulin levels. No significant differences were found be-
tween the 3 groups for any of these variables and the nutri-
ent intake profile (Table 1).
The HbA1c level and BMI before and after the treatment
are shown in Figure 2. In the placebo group, HbA1c levels
were increased in 11 patients (69%) after the treatment;ligibility (n=74)
ed (n = 66)
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Table 1 Patients’ characteristics and nutrient intake profiles
Placebo (n = 20) TGD 300 mg/day (n = 20) TGD 900 mg/day (n = 20) p value
Characteristic
Sex (male/female) 9/11 14/6 12/8 0.272
Age (year) 61.8 ± 8.1 62.4 ± 10.3 62.7 ± 8.3 0.928
Body mass index (kg/m2) 22.8 ± 4.2 25.1 ± 4.8 23.2 ± 3.1 0.187
HbA1c (%) 6.9 ± 0.7 6.7 ± 0.5 6.7 ± 0.4 0.319
Fasting blood glucose (mg/dL) 141.4 ± 35.3 143.8 ± 20.1 148.8 ± 23.7 0.677
Insulin (mU/mL) 9.2 ± 8.1 13.7 ± 17.5 13.2 ± 21.9 0.651
Nutrients
Energy (Kcal) 1565 ± 320 1768 ± 417 1671 ± 321 0.203
Protein (g) 51.3 ± 11.1 56.9 ± 11.7 52.7 ± 8.4 0.203
Fat (g) 39.8 ± 7.3 45.0 ± 10.3 39.3 ± 8.2 0.069
Cholesterol (mg) 254 ± 80 234 ± 53 235 ± 64 0.548
Ongoing diabetes therapies, n (%)
Insulin injection 3 (15) 2 (10) 6 (30) 0.235
Metoformin 5 (25) 7 (35) 5 (25) 0.720
Insulin secretagogue 13 (65) 12 (60) 9 (45) 0.414
α-Glicosidase inhibitor 8 (40) 10 (50) 10 (50) 0.765
PPAR-γ antagonist 5 (25) 5 (25) 5 (25) 1.000
≥2 diabetes drugs 11 (55) 11 (55) 9 (45) 0.766
Lifestyle modification only 2 (4) 1 (5) 2 (4) 0.804
TGD, transglucosidase; HbA1c, glycolated hemoglobin.
Sasaki et al. BMC Gastroenterology 2013, 13:81 Page 4 of 7
http://www.biomedcentral.com/1471-230X/13/81levels were higher but not significant than those in the
TGD-treated group (14 [39%]; p = 0.07). In the placebo
group, the BMI had increased in 9 patients (56%) after the
treatment; the BMIs were higher than that in the TGD-
treated group (14 [39%]).
A total of 10 healthy individuals (7 men and 3 women)
were recruited for comparison of their fecal microbiota
with those of the T2DM patients by dendrogram. The %
AUC was associated with the predominance of bacterial
species that compose each peak. Significant decreases in















Figure 2 The HbA1c levels and BMIs before and after the treatment.Clostridium subcluster XIVa components (OTUs of 106,
494, 505, 517, 754, 955, and 990 bp) were observed in the
T2DM patients compared with the healthy individuals. In
contrast, the Lactobacillales (OTUs of 332, 520, and 657
bp) and Bifidobacterium populations (OTUs of 124 bp) sig-
nificantly increased in the T2DM patients (Figure 3).
The fecal bacterial communities were analyzed using a
dendrogram. Setting the similarity cutoff at 40% generated
4 major clusters. Most of the healthy individuals (6/10) and
T2DM patients (45/60) were classified into cluster I,
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Figure 3 Gut microbes in the healthy individuals and T2DM
patients. Significant decreases in Clostridium cluster IV and
Clostridium subcluster XIVa components were observed in the T2DM
patients compared with the healthy individuals. In contrast, the
Lactobacillales and Bifidobacterium populations significantly increased






Figure 4 Dendrogram of the fecal bacteria structure in the
T2DM patients and healthy individuals. T-RFLP patterns by BslI
digestions were analyzed using the software GeneMaths (Applied
Maths, Belgium), and the Pearson similarity coefficient analysis and
unweighted pair-group method with arithmetic means were used to
establish the type of dendrogram. Open triangle, healthy volunteers;
open square, T2DM patients before the placebo treatment; closed
square, T2DM patients after the placebo treatment; open circle,
T2DM patients before the treatment; closed circle, T2DM patients
after the treatment.
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patients. In the placebo and TGD groups, the bacterial
communities were generally similar before and after the
treatment. These results suggest that bacterial lineages were
constant within each individual (Figure 4).
To investigate the effects of TGD on fecal bacterial com-
munities, the Bacteroidetes-to-Firmicutes ratios in the pla-
cebo, TGD300, and TGD900 groups were analyzed
(Figure 5). Before the TGD therapy, no significant differ-
ence was observed in the Bacteroidetes -to-Firmicutes ra-
tios between the 3 groups. However, the mean size of the
Firmicutes populations (49.0%) in the T2DM patients was
significantly smaller than that in the healthy patients
(58.6%; p < 0.05). After 12 weeks of TGD therapy, the
Bacteroidetes-to-Firmicutes ratios in both TGD groups sig-
nificantly increased compared with that before the TGD
treatment and were also significantly higher than that in
the placebo group, indicating improvement of gut micro-
biota. No significant change in Bacteroidetes-to-Firmicutes
ratio was observed in the placebo group before and after
the treatment. In the group with an increase in
Bacteroidetes-to-Firmicutes ratio, 50% (12/24) and 48%
(11/23) of the patients had decreased HbA1c levels and
BMIs, respectively, after the TGD treatment; however, in
the group without an increased Bacteroidetes-to-Firmicutes
ratio, only 22% (2/9) and 33% (3/9) of the patients had de-
creased HbA1c levels and BMIs, respectively, after the
TGD treatment.
No serious adverse events were attributable to TGD
administration.
Discussion
T2DM is a metabolic disease primarily caused by
obesity-linked insulin resistance. Recent studies haveshown a relationship between intestinal microbiota com-
position and metabolic diseases such as obesity and dia-
betes. Two groups of beneficial bacteria, Bacteroidetes and




























Figure 5 Bacteroidetes-to-Firmicutes ratio before and after the
TGD treatment in the T2DM patients. After the TGD therapy, the
Bacteroidetes-to-Firmicutes ratio in both TGD groups significantly
increased compared with that before the TGD treatment and was
also significantly higher than that in the placebo group.
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creased in obese people in comparison with lean people
and that this proportion increased with weight loss on a
low-energy diet. They also demonstrated that obese
(ob/ob) mice had 50% fewer Bacteroidetes and corres-
pondingly more Firmicutes than their lean (+/+) sib-
lings [5]. Backhed et al. [4] transplanted gut microbiota
from healthy mice into germ-free recipients, which dem-
onstrated an increase in body fat without any increase in
food consumption, raising the possibility that the micro-
bial community composition in the gut affects the amount
of energy extract from the diet [4]. These results further
indicate that obesity has a microbial component, which
might have potential therapeutic implications.
T2DM is a complex disorder influenced by genetic
and environmental components. A genome-wide associ-
ation study is useful for parsing the underlying genetic
contributors to T2DM, focusing on identifying genetic
components in an organism’s genome. Recently, the risk
factors for T2DM was observed to involve other ge-
nomes; hence, a metagenome-wide association study
should also be performed to analyze intestinal micro-
biota content [12]. Larsen et al. [12] indicated that the
proportion of Firmicutes was significantly reduced in
T2DM patients. Schwiertz and colleagues [13] also
obtained lower Firmicutes-to-Bacteroidetes ratios in over-
weight human adults than in lean controls, consistent with
our results that smaller Firmicutes populations were ob-
served in the T2DM patients than in the healthy patients.
Several studies on mice and human models provided evi-
dence, albeit controversial, that increase in body weight is
associated with a large proportion of Firmicutes and rela-
tively small proportion of Bacteroidetes [4,5,7]. In relation
to T2DM, the present study demonstrated an increase inBifidobacterium population in the T2DM patients. On the
contrary, Wu et al. [14] observed a decrease in
Bifidobacterium population by PCR-denaturing gradient gel
electrophoresis analysis. This discrepancy in results may be
due to the difference in methodology between our study
and that of Wu et al.
The results of the present trial suggest that the TGD ad-
ministration improved the body weights and blood glucose
levels of the T2DM patients, probably owing to the TGD-
induced production of oligosaccharides in the alimentary
tract. Dietary fibers of natural and synthetic origins have
gained increasing attention because of their beneficial effects
of lowering blood glucose and lipid levels and protecting
against heart disease [15-17]. However, some reports indi-
cated that dietary fibers have no effect on blood glucose and
lipid concentrations [18]. This discrepancy in findings may
be due to the reductive effect of oligosaccharide on post-
prandial hyperglycemia, which is dependent on the compos-
ition of the diet [16]. In the present study, because all the
diabetic patients received nourishment guidance at the be-
ginning of the treatment, no significant difference in their
eating habits was observed, which was confirmed by the
questionnaire survey. Using rat gastrointestinal and gastric
ligation models, we previously demonstrated that TGD can
convert carbohydrates to oligosaccharides [8]. Products
such as panose and isomaltooligosaccharide, which are
predominantly utilized by bifidobacteria [19], are indigest-
ible oligosaccharides that reach the cecum. We have previ-
ously proposed that the consumption of TGD can reduce
the total amount of orally ingested calories via the conse-
quent transformation of digestible substrate to indigestible
fiber in the alimentary tract [2]. The reduction in total cal-
orie intake and the effect of the oligosaccharides generated
by TGD can explain the reduction in blood glucose and
lipid concentrations observed in this study. Another mech-
anism to explain the outcome of this trial may be the im-
provement in gut microbiota composition, as evident by
the increase in the Bacteroidetes-to-Firmicutes ratio. Our
study supports the finding of Ley et al. that Bacteroidetes
abundance was increased according to the decrease in the
body weights of obese individuals by dietary treatment [6].
In summary, we indicated that T2DM in humans is as-
sociated with compositional changes in intestinal micro-
biota, and TGD treatment improved metabolic condition
of T2DM and fecal microbiota. These evidence suggests
that there is the link between metabolic disease and bac-
terial population in the gut.Conclusions
Therefore, based on the results of the present trial, we sug-
gest that the TGD treatment decreased the blood glucose
levels and prevented body weight gain in the T2DM
patients by inducing the production of oligosaccharides in
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